127 related articles for article (PubMed ID: 6112842)
1. Discontinuing antiparkinson medication in chronic schizophrenics. At what cost to the patient?
Manos N; Gkiouzepas J
Acta Psychiatr Scand; 1981 Jan; 63(1):28-32. PubMed ID: 6112842
[TBL] [Abstract][Full Text] [Related]
2. Gradual withdrawal of antiparkinson medication in chronic schizophrenics: any better than the abrupt?
Manos N; Gkiouzepas J; Tzotzoras T; Tzanetoglou A
J Nerv Ment Dis; 1981 Oct; 169(10):659-61. PubMed ID: 6116743
[TBL] [Abstract][Full Text] [Related]
3. The need for continuous use of antiparkinsonian medication with chronic schizophrenic patients receiving long-term neuroleptic therapy.
Manos N; Gkiouzepas J; Logothetis J
Am J Psychiatry; 1981 Feb; 138(2):184-8. PubMed ID: 6109453
[TBL] [Abstract][Full Text] [Related]
4. Biperiden withdrawal in schizophrenic inpatients receiving long-term antipsychotic medication.
Wada Y; Koshino Y; Yamaguchi N
Clin Neuropharmacol; 1987 Aug; 10(4):370-5. PubMed ID: 2902920
[TBL] [Abstract][Full Text] [Related]
5. Mood elevating effect of trihexyphenidyl and biperiden in individuals taking antipsychotic medication.
Jellinek T
Dis Nerv Syst; 1977 May; 38(5):353-5. PubMed ID: 852367
[TBL] [Abstract][Full Text] [Related]
6. The rabbit syndrome and antiparkinsonian medication in schizophrenic patients.
Wada Y; Yamaguchi N
Neuropsychobiology; 1992; 25(3):149-52. PubMed ID: 1357583
[TBL] [Abstract][Full Text] [Related]
7. Differential memory function with dopaminergic versus anticholinergic treatment of drug-induced extrapyramidal symptoms.
Fayen M; Goldman MB; Moulthrop MA; Luchins DJ
Am J Psychiatry; 1988 Apr; 145(4):483-6. PubMed ID: 2894780
[TBL] [Abstract][Full Text] [Related]
8. Biperiden and haloperidol plasma levels and extrapyramidal side effects in schizophrenic patients.
Meszaros K; Lenzinger E; Hornik K; Schönbeck G; Hatzinger R; Langer G; Sieghart W; Aschauer HN
Neuropsychobiology; 1997; 36(2):69-72. PubMed ID: 9267855
[TBL] [Abstract][Full Text] [Related]
9. [Dependence on anticholinergics among schizophrenics. Iatrogenic disease or self-medication?].
Chamorro García L
Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1991; 19(6):298-303. PubMed ID: 1687233
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the need for prophylactic antiparkinsonian medication in psychotic patients treated with neuroleptics.
Manos N; Lavrentiadis G; Gkiouzepas J
J Clin Psychiatry; 1986 Mar; 47(3):114-6. PubMed ID: 2869027
[TBL] [Abstract][Full Text] [Related]
11. [A differential approach to the improvement of prevention and correction of neuroleptic side extrapyramidal disorders with pantogam activ in patients with schizophrenia].
Tiganov AS; Panteleeva GP; Abramova LI; Bologov PV; Kananovich PS; Omel'chenko MA; Nikiforova IY
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(2):72-80. PubMed ID: 28374697
[TBL] [Abstract][Full Text] [Related]
12. Antiparkinsonian prescription and extrapyramidal symptoms.
Grover S; Kulhara P
Br J Psychiatry; 2006 May; 188():492; author reply 492-3. PubMed ID: 16648544
[No Abstract] [Full Text] [Related]
13. Evaluating the long-term need for antiparkinson drugs by chronic schizophrenics.
Klett CJ; Caffey E
Arch Gen Psychiatry; 1972 Apr; 26(4):374-9. PubMed ID: 4552131
[No Abstract] [Full Text] [Related]
14. The withdrawal of benztropine mesylate in chronic schizophrenic patients.
Baker LA; Cheng LY; Amara IB
Br J Psychiatry; 1983 Dec; 143():584-90. PubMed ID: 6362765
[TBL] [Abstract][Full Text] [Related]
15. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses.
Cesková E; Svestka J
Pharmacopsychiatry; 1993 Jul; 26(4):121-4. PubMed ID: 7694306
[TBL] [Abstract][Full Text] [Related]
16. [Withdrawal of antiparkinson drugs in long term neuroleptic treatment].
Lerner J; Blum E; Fuchs I; Grinberg M
Harefuah; 1978 Oct; 95(8):239-41. PubMed ID: 33879
[No Abstract] [Full Text] [Related]
17. Adverse effects of antiparkinson drug withdrawal.
Jellinek T; Gardos G; Cole JO
Am J Psychiatry; 1981 Dec; 138(12):1567-71. PubMed ID: 6118066
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial.
Wynchank D; Berk M
Hum Psychopharmacol; 2003 Jun; 18(4):271-5. PubMed ID: 12766931
[TBL] [Abstract][Full Text] [Related]
19. A double-blind crossover comparison of antiparkinson drug therapy: amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function.
McEvoy JP
J Clin Psychiatry; 1987 Sep; 48 Suppl():20-3. PubMed ID: 2887553
[TBL] [Abstract][Full Text] [Related]
20. Anticholinergics to treat antipsychotic-induced extrapyramidal symptoms: Time to avoid this practice.
Koola MM
Asian J Psychiatr; 2018 Jan; 31():100-101. PubMed ID: 29454175
[No Abstract] [Full Text] [Related]
[Next] [New Search]
